AstraZeneca’s Ultomiris Shows Phase 3 Breakthrough in IgAN
Cambridge, United Kingdom – April 21, 2026 AstraZeneca announced that its complement inhibitor Ultomiris® (ravulizumab) achieved statistically significant and...
Ultomiris
Advertisement
Advertisement
